By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ProNAi Therapeutics, Inc. 

4717 Campus Drive
Suite 1100
Kalamazoo  Michigan  49008  U.S.A.
Phone: 269-372-3289 Fax: 269-544-1079


SEARCH JOBS








Company News
ProNAi Therapeutics, Inc. Names New President And Chief Executive Officer 9/3/2014 9:03:12 AM
ProNAi Therapeutics, Inc. Banks $59.5 Million Series D To Fund Non-Hodgkin's Lymphoma Studies 4/21/2014 4:22:07 PM
ProNAi Therapeutics, Inc. Secures $12 Million Series C Financing To Expand Phase II Cancer Studies For PNT2258, A Novel BCL2 Inhibitor, In Defined Lymphoma Patients 1/13/2014 8:17:05 AM
ProNAi Therapeutics, Inc. Reports Anti-Tumor Activity From Ongoing Phase II Clinical Study Of PNT2258, A Novel BCL2-Inhibitor, At American Society of Hematology Annual Meeting 12/10/2013 7:03:32 AM
ProNAi Therapeutics, Inc. to Present Phase II Clinical Data at American Society of Hematology for PNT2258, a BCL2 Targeted Drug 11/8/2013 7:52:07 AM
Marina Biotech, Inc. Announces That Licensee ProNAi Therapeutics, Inc. Reported Phase 1 Study Results Using SMARTICLES® Nucleic Acid Delivery Technology 12/5/2012 9:42:39 AM
ProNAi Therapeutics, Inc. Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting 11/12/2012 8:52:08 AM
Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) and ProNAi Therapeutics, Inc. Announce License Agreement for Up to $14 Million 3/14/2012 6:52:23 AM
ProNAi Therapeutics, Inc. Cleared to Begin Phase I Clinical Trials for the First DNA Interference (DNAi(R)) Therapeutic 3/20/2008 6:20:13 AM
ProNAi Therapeutics, Inc. Announces First DNAi(R) Mechanism of Action Studies for PNT2258 Oncology Drug Candidate 8/23/2007 9:07:05 AM
12
//-->